AstraZeneca plc 2.6% Potential Upside Indicated by Deutsche Bank

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

AstraZeneca plc using EPIC/TICKER code (LON:AZN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Deutsche Bank. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set a target price of 7600 GBX on its stock. This indicates the analyst now believes there is a potential upside of 2.6% from the opening price of 7407 GBX. Over the last 30 and 90 trading days the company share price has increased 308 points and increased 1481 points respectively. The 52 week high for the share price is currently at 7565.59 GBX while the year low share price is currently 5312 GBX.

AstraZeneca plc has a 50 day moving average of 6,916.11 GBX and the 200 Day Moving Average price is recorded at 6,266.42. There are currently 1,311,876,336 shares in issue with the average daily volume traded being 2,391,745. Market capitalisation for LON:AZN is £99,222,453,515 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.
    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
    AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.

      Search

      Search